Research programme: iPSC derived chimeric antigen receptor NK-cell therapeutics - Fate Therapeutics/Ono Pharmaceutical

Alternative Names: iPSC derived CAR NK-cell therapeutics - Fate Therapeutics/Ono Pharmaceutical

Latest Information Update: 12 Jul 2022

Price :

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

Originator Memorial Sloan-Kettering Cancer Center
Developer Fate Therapeutics; Ono Pharmaceutical
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jun 2022 Fate Therapeutics and Ono Pharmaceutical collaborate to develop CAR-NK cell therapies for Solid tumours
28 Jun 2022 Fate Therapeutics has patent protection for iPSC product platform worldwide
28 Jun 2022 Fate Therapeutics has patents pending for iPSC product platform worldwide

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com